Our Curious Amalgam Podcast

What Are the Generic and Biosimilar Industries Worried About? Current Competition Law Issues Impacting the Sector

May 10, 2021

Play Podcast

London partner Matthew Hall co-hosted the May 10 episode of the ABA's Our Curious Amalgam podcast on the topic "What Are the Generic and Biosimilar Industries Worried About? Current Competition Law Issues Impacting the Sector."

Generics and biosimilars are an important part of the pharmaceutical landscape in Europe. What are the competition law issues faced by suppliers of those products? Adrian van den Hoven, Director General of trade association Medicines for Europe, joins John Roberti and Matthew Hall to discuss the key concerns of generic and biosimilar suppliers and also the dramatic impact of COVID-19 on them. Listen to this episode to learn more about the application of competition law to pharmaceuticals and the background to the 2020 comfort letter granted by the European Commission at the request of Medicines for Europe.

Our Curious Amalgam explores topics in antitrust, competition, consumer protection, data protection, and privacy law around the world with leading experts in those areas. It is an amalgam because it is a group of diverse topics all in one place. It is curious because it gets the experts and asks them in-depth questions.

This episode is also available on Apple Podcasts.

Back to top